AURKA was able to distinguish HCV+ HCC patients from healthy controls in three datasets (GSE69715, GSE107170, and TCGA‐LIHC), with AUCs higher than 0.71 (TCGA‐LIHC dataset, AUC = 0.986),75 thus demonstrating the consistency of AURKA as a potential diagnostic biomarker. Here, AURKA is linked to hepatocellular carcinoma.